{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:07:00Z","timestamp":1772777220191,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jcjo.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:37:13Z","timestamp":1678772233000},"page":"e161-e169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of anti-vascular endothelial growth factor discontinuation in neovascular age-related macular degeneration"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-5321","authenticated-orcid":false,"given":"Amy","family":"Basilious","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7610-432X","authenticated-orcid":false,"given":"Bobbi","family":"Smuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monali S.","family":"Malvankar-Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena R.","family":"Juncal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-1857","authenticated-orcid":false,"given":"Tom G.","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2023.02.006_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00417-021-05246-5","article-title":"Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections","volume":"260","author":"Rosenblatt","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0002","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","article-title":"Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration","volume":"34","author":"Vaze","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0003","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.4103\/ijo.IJO_3066_21","article-title":"Patterns of treatment discontinuation in patients receiving anti\u2013vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"70","author":"Dhingra","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0005","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.2147\/OPTH.S325763","article-title":"Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration","volume":"15","author":"Sobolewska","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/PPA.S347713","article-title":"Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study","volume":"16","author":"Giocanti-Aur\u00e9gan","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0007","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.3390\/jcm10143106","article-title":"Factors of anti\u2013vascular endothelial growth factor therapy withdrawal in patients with neovascular age-related macular degeneration: implications for improving patient adherence","volume":"10","author":"Gomi","year":"2021","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.jcjo.2023.02.006_bib0008","article-title":"Impact on caregivers of patients with eye diseases: systematic review and meta-analysis","volume":"S0008-4182","author":"Pur","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0009","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","article-title":"Systematic review: non-adherence and non-persistence in intravitreal treatment","volume":"258","author":"Ehlken","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211026389","article-title":"The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"12","author":"Zhao","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0011","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/IAE.0000000000003369","article-title":"Treatment deferral during COVID-19 lockdown: functional and anatomical impact on patients with neovascular age-related macular degeneration","volume":"42","author":"Montesel","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0012","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","article-title":"Defining nonadherence and nonpersistence to anti\u2013vascular endothelial growth factor therapies in neovascular age-related macular degeneration","volume":"139","author":"Okada","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0013","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1097\/IAE.0000000000002272","article-title":"Age-related macular degeneration-associated peripapillary choroidal neovascularization in the era of anti-vascular endothelial growth factor","volume":"39","author":"Lin","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/09286586.2017.1397701","article-title":"Risk factors for discontinuation of treatment for neovascular age-related macular degeneration","volume":"25","author":"Westborg","year":"2018","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0015","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ICU.0000000000000782","article-title":"Artificial intelligence\u2013based predictions in neovascular age-related macular degeneration","volume":"32","author":"Ferrara","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","article-title":"Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review","volume":"42","author":"Chaudhary","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0018","unstructured":"Canadian Retina Society. CRS position statement on intravitreal injection treatments 2020. Ottawa: CRS. https:\/\/crsscr.ca\/2020\/03\/canadian-retina-society-crs-position-statement-on-intravitreal-injections-and-the-management-of-retinal-diseases-during-the-covid-19-crisis\/. Accessed: March 19, 2020."},{"key":"10.1016\/j.jcjo.2023.02.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/25158414211070881","article-title":"Impact of COVID-19-associated anxiety on the adherence to intravitreal injection in patients with macular diseases a year after the initial outbreak","volume":"14","author":"Liu","year":"2022","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0020","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti\u2013vascular endothelial growth factor injections","volume":"136","author":"Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0021","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti\u2013vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0022","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2022.06.005","article-title":"Anti\u2013vascular endothelial growth factor treatment discontinuation and interval in neovascular age-related macular degeneration in the United States","volume":"242","author":"Bakri","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0024","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","article-title":"Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life","volume":"251","author":"Droege","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40123-022-00452-8","article-title":"Intravitreal aflibercept therapy and treatment outcomes of eyes with neovascular age-related macular degeneration in a real-life setting: a five-year follow-up investigation","volume":"11","author":"Angermann","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0026","article-title":"Easing the anti-VEGF treatment burden","author":"McKinney","year":"2020","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0027","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/IAE.0000000000003512","article-title":"Delayed follow-up in patients with neovascular age-related macular degeneration treated under universal health coverage: risk factors and visual outcomes","volume":"42","author":"Rozon","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.02.006_bib0028","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4103\/ijo.IJO_738_21","article-title":"Insurance coverage for intravitreal injections in India\u2014the road ahead","volume":"69","author":"Narayanan","year":"2021","journal-title":"Indian J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T11:34:16Z","timestamp":1711193656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418223000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0008418223000467"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.02.006","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of anti-vascular endothelial growth factor discontinuation in neovascular age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}